ISN Webinar: Pioneering Xenotransplantation: The World’s First Genetically-Edited Pig Kidney Transplant in a Living Recipient
- 2 PM CET
The groundbreaking achievement of the world’s first genetically-edited pig kidney transplant into a living recipient marks a significant milestone in the field of organ transplantation and regenerative medicine. This webinar will delve into the scientific, ethical, and clinical aspects of this pioneering procedure, exploring the cutting-edge techniques of genetic editing that made this xenotransplantation possible. Attendees will gain an in-depth understanding of the CRISPR technology used to modify the pig kidney, the challenges and solutions involved in overcoming immune rejection, and the implications this innovation holds for addressing the global organ shortage. Additionally, the session will examine the clinical outcomes observed in the recipient, discuss the potential risks, and evaluate the future of xenotransplantation in mainstream medical practice. This webinar is essential for healthcare professionals, researchers, and bioethicists interested in the future of organ transplantation and the role of genetic engineering in medical breakthroughs.
Learning objectives:
- Gain a comprehensive understanding of the CRISPR technology and other genetic modification methods employed to create a genetically-edited pig kidney suitable for human transplantation, including the steps taken to minimize immune rejection and other complications.
- Assess the clinical results of the world’s first genetically-edited pig kidney transplant into a living recipient, including both the short-term and potential long-term outcomes, and explore the ethical implications and societal impacts of using genetically modified animal organs in human patients.
- Investigate the broader implications of this pioneering transplant for the future of organ transplantation, including its potential to alleviate the global organ shortage, the challenges that remain, and the steps necessary to bring xenotransplantation into widespread clinical use.
Moderators
Li-Li Hsiao (USA)
Speakers
Leonardo V. Riella (USA)
Winfred Williams (USA)